214 related articles for article (PubMed ID: 37921936)
1. The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer-Quo Vadimus?
Ong WL; Loblaw A
World J Urol; 2023 Dec; 41(12):3485-3491. PubMed ID: 37921936
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806).
Isfahanian N; Lukka H; Dayes I; Quan K; Schnarr KL; Douvi G; Goldberg M; Wright J; Swaminath A; Chow T; Diamond K; Cutz JC; Kavsak P; Thabane L; Tsakiridis T
Clin Genitourin Cancer; 2020 Aug; 18(4):e410-e415. PubMed ID: 32265129
[TBL] [Abstract][Full Text] [Related]
3. Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.
Jiang P; Krockenberger K; Vonthein R; Tereszczuk J; Schreiber A; Liebau S; Huttenlocher S; Imhoff D; Balermpas P; Keller C; Dellas K; Baumann R; Rödel C; Hildebrandt G; Jünemann KP; Merseburger AS; Katz A; Ziegler A; Blanck O; Dunst J
Radiat Oncol; 2017 Aug; 12(1):138. PubMed ID: 28821268
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC; Ostler P; van der Voet H; Chu W; Loblaw A; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Armstrong J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Duffton A; Brand DH; Henderson D; Morrison K; Brown S; Pugh J; Burnett S; Mahmud M; Hinder V; Naismith O; Hall E; van As N;
Lancet Oncol; 2022 Oct; 23(10):1308-1320. PubMed ID: 36113498
[TBL] [Abstract][Full Text] [Related]
5. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
6. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
7. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
9. Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer.
Poon DMC; Lam D; Wong KCW; Chu CM; Cheung M; Mo F; Suen J; Ng CF; Chan ATC
Curr Oncol; 2021 Dec; 29(1):27-37. PubMed ID: 35049677
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.
Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC
Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102
[TBL] [Abstract][Full Text] [Related]
12. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
Phuong C; Chan JW; Ni L; Wall P; Mohamad O; Wong AC; Hsu IC; Chang AJ
Radiat Oncol; 2022 Jan; 17(1):12. PubMed ID: 35057827
[TBL] [Abstract][Full Text] [Related]
13. ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial.
Zilli T; Scorsetti M; Zwahlen D; Franzese C; Förster R; Giaj-Levra N; Koutsouvelis N; Bertaut A; Zimmermann M; D'Agostino GR; Alongi F; Guckenberger M; Miralbell R
Radiat Oncol; 2018 Sep; 13(1):166. PubMed ID: 30180867
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results.
Aluwini S; van Rooij P; Hoogeman M; Kirkels W; Kolkman-Deurloo IK; Bangma C
Radiat Oncol; 2013 Apr; 8():84. PubMed ID: 23570391
[TBL] [Abstract][Full Text] [Related]
15. Secondary cancer risk from modern external-beam radiotherapy of prostate cancer patients: Impact of fractionation and dose distribution.
Sitathanee C; Tangboonduangjit P; Dhanachai M; Suntiwong S; Yongvithisatid P; Rutchantuk S; Changkaew P; Watjiranon R; Khachonkham S; Boonkitticharoen V
J Radiat Res; 2021 Jul; 62(4):707-717. PubMed ID: 33993271
[TBL] [Abstract][Full Text] [Related]
16. Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers.
Hu HP; Anagnostopoulos G; Gouran-Savadkoohi M; Dayes I; Ishkanian A; Hallock A; Lukka H; Quan K; Schnarr K; Cuthbert D; Goldberg M; Chang YM; Tsakiridis T
Prostate; 2024 Feb; 84(2):193-202. PubMed ID: 37880911
[TBL] [Abstract][Full Text] [Related]
17. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
Royce TJ; Mavroidis P; Wang K; Falchook AD; Sheets NC; Fuller DB; Collins SP; El Naqa I; Song DY; Ding GX; Nahum AE; Jackson A; Grimm J; Yorke E; Chen RC
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):227-236. PubMed ID: 32900561
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?
Roy S; Morgan SC
Curr Urol Rep; 2019 Jul; 20(9):53. PubMed ID: 31359187
[TBL] [Abstract][Full Text] [Related]
19. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
